PDB88 - Amnog Early Benefit Assessment (EBA) in Germany - A Specific Challenge for Antidiabetics

Autor:	Bleß, H, Mathes, J, Kotowa, W, Lübker, C
Zdroj:	In Value in Health November 2016 19(7):A680-A681
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect